Allogeneic ABCB5⁺ mesenchymal stem cells for treatment-refractory chronic venous ulcers: a phase I/IIa clinical trial.

ABSTRACT: A significant number of chronic venous ulcers (CVUs) fail to heal despite of guideline-conform standard of care. Skin-derived ABCB5⁺ mesenchymal stem cells (MSCs) can dampen the sustained IL-1β-driven inflammation present in chronic wounds. Based on their wound healing-facilitating effects in a mouse CVU model and an autologous first-in-human study, ABCB5⁺ MSCs have emerged as a potential candidate for cell-based advanced therapy of non-healing CVUs. In the present interventional, multicenter, single-arm, phase I/IIa clinical trial, subjects whose CVU had emerged as standard therapy-resistant received one or two topical applications of 1×10⁶ allogeneic ABCB5⁺ MSCs/cm² wound area in addition to standard treatment. Out of 83 treatment-em

SUBMITTER: Kerstan A 

PROVIDER: S-EPMC8635035 | biostudies-literature | 2022 Jan

REPOSITORIES: biostudies-literature